#cambrex

Cambrex Expands Biopharmaceutical Services Business

Cambrex (CBM:NYS) Fundamental Valuation Report

Print This Report was generated using the tools available on StockCalc.com. Patchell Brook Equity Analytics Inc. emphasizes that the user assumes all risks associated with the use of this report or the Stockcalc website including, but not limited to, all terms and conditions mentioned in the legal disclaimer. To access all of the tools on Stockcalc, including more detailed valuation reports and…

Cambrex completes small-scale API expansion at Iowa plant

Cambrex Corporation (CBM) has completed an expansion of cGMP small-scale capacity at its Charles City, Iowa plant.

The project has seen the installation of two 500-gallon glass-lined reactors and creates a third small-scale work centre, further increasing flexibility for customer projects.

This latest investment follows the completion of an expansion of large-scale manufacturing capabilities and an announcement of the construction of a $24M, 4,500 sq. ft highly potent active pharmaceutical ingredient (HPAPI) manufacturing facility at Charles city, which is due to open in 2019.

Cambrex’s Charles City, Iowa facility is located on a 45-acre site and manufactures a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances.

Cambrex to expand pilot plant in US; invests $2.4 mn

EAST RUTHERFORD, US: Cambrex Corporation (CBM) to expand its pilot plant capabilities at its High Point, North Carolina facility with the installation of a fourth reactor suite. The $2.4 million investment will increase the site’s reactor capacity by around 30 percent.

The new 400 sq ft suite, which is being constructed to meet growing business demand, will feature two 2000 litre reactors and a 0.6 sq m Hastelloy filter dryer and is expected to be fully operational by early 2018.

In a second investment at the High Point site, Cambrex is to upgrade its analytical chromatography data systems for quality control and analytical R&D to new, Empower 3 software. Empower will be introduced in Q3 and Q4 of 2017 and will bring enhanced capability, integrity and compliance to the site’s analytical systems, in line with the increasingly stringent demands of the FDA and EMA among other agencies.

“This expansion will facilitate the scheduling of current good manufacturing practices (cGMP) campaigns for our customers and assist in meeting clinical deadlines. In addition, with the new filter dryer we will be able to run small scale batches to demonstrate their feasibility for scale-up,” said Brian Swierenga, VP, operations and site director, Cambrex High Point.

New Post has been published on http://www.stockmarketsdaily.com/biotech-value-buys-amgen-nasdaqamgn-cambrex-nysecbm-biogen-idec-nasdaqbiib/7771/

Biotech Value Buys: Amgen (NASDAQ:AMGN), Cambrex (NYSE:CBM), Biogen Idec (NASDAQ:BIIB)

(adsbygoogle = window.adsbygoogle || []).push();

Amgen Inc (NASDAQ:AMGN), Cambrex Corporation (NYSE:CBM), and Biogen Idec Inc (NASDAQ:BIIB) are 3 biotech companies getting a lot of attention at the moment. So we decided to assess which may provide the best value for investors to consider buying and which are over, under or fairly priced.

Rather than the usual Price to Earnings (P/E) multiple method, we feel the best way to assess which of Amgen (AMGN), Cambrex (CBM), Biogen Idec (BIIB) is the best value currently is to use the PEG ratio (P/E to growth). This PEG multiple takes into account the expected long term growth in earnings of the companies rather than merely the growth for one earnings period ahead as forward P/E does. As a rule of thumb, a stock with a PEG of between 0 and 1 is usually considered to be underpriced, between 1 and 2 to be at fair value and over 2 to be overpriced.

Amgen (NASDAQ:AMGN) had a last closing stock price of $152.26 after moving -2.63% in trading with a trailing 12 month P/E multiple of 23.98 and an estimated forward P/E multiple of 16.40. Amgen (AMGN) has an estimated 5 year annual growth of 11.33% and a PEG multiple of 2.12. Based on the PEG ratio of AMGN being 2.12, we consider Amgen to likely be overpriced.

Cambrex (NYSE:CBM) had a last closing stock price of $22.43 after moving -1.92% in trading with a trailing 12 month P/E multiple of 17.80 and an estimated forward P/E multiple of 17.03. Cambrex (CBM) has an estimated 5 year annual growth of 21.00% and a PEG multiple of 0.85. Based on the PEG ratio of CBM being 0.85, we consider Cambrex to likely be underpriced.

Biogen Idec (NASDAQ:BIIB) had a last closing stock price of $389.16 after moving 10.17% in trading with a trailing 12 month P/E multiple of 36.82 and an estimated forward P/E multiple of 23.76. Biogen Idec (BIIB) has an estimated 5 year annual growth of 22.62% and a PEG multiple of 1.63. Based on the PEG ratio of BIIB being 1.63, we consider Biogen Idec to likely be at fair value.

Based on the above, it would appear that Cambrex offers the best value, as it has the lowest PEG ratio of 0.85, when compared to the other stocks. This makes it appear less expensive due to having a lower stock price against current earnings and predicted growth in those earnings in the coming 5 years.